Chlorpyrifos Lab Report

Absorption

Absorption of chlorpyrifos varies with species to species. In humans, about 70% was absorbed after oral exposure of volunteers. For the metabolite, 3, 5, 6-trichloro-2-pyridinol (TCPY), the minimal dermal absorption was 1-3%. It is to be noted that chlorpyrifos (cpf) is rapidly absorbed and transported to the brain through oral dosing [66].
Distribution
The highest tissue concentrations were found inorgan such as the liver and kidney, but chloropyrifos (cpf) did not bioconcentrate in tissue at the time of study when pregnant rats were dosed with CPF at 7 mg/kg-day on GD 14–18, fetal brain TCPY concentration was twice as high as the maternal brain concentration, 5 hours after the last dose of CPF[67].
Metabolism
The metabolic scheme for CPF is described below. Chlorpyrifos is bioactivated

Initial signs and symptomsof chlopyrifos include irritation in the eyes, increased saliva and sweat production, nausea, runny nose, dizziness and headache. Signs of progression include muscle twitching, weakness or tremors, lack of coordination, vomiting, darkened vision, abdominal cramps, diarrhoea, and pupil constriction with blurred vision.Signs of severe toxicity of chlorpyrifos include increased heart rate, unconsciousness, respiratory depression loss of control of the urine or bowels, convulsions, , and paralysis . Psychiatric symptoms associated with acute exposure of chlorpyrifos (CPF) include anxiety, bizarre behavior, depression, memory loss, confusion, stupor, and restlessness.CPF toxicity in children are reported lethargy,coma, weakness, pupil constriction, and excess salivation . Decrease heart rate, muscle weakness, sweating and increase tear production are reported in adult. . Acute and chronic dose exposures to CPF in humans suffer an intermediate syndrome. After exposure of organophosphate, signs and symptoms typically occur in 24-96 hours